CN105617382A - miRNA-543-3p在帕金森病的诊断和治疗中的应用 - Google Patents
miRNA-543-3p在帕金森病的诊断和治疗中的应用 Download PDFInfo
- Publication number
- CN105617382A CN105617382A CN201511029276.3A CN201511029276A CN105617382A CN 105617382 A CN105617382 A CN 105617382A CN 201511029276 A CN201511029276 A CN 201511029276A CN 105617382 A CN105617382 A CN 105617382A
- Authority
- CN
- China
- Prior art keywords
- mirna
- glt
- mir
- expression
- glutamate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
Description
试剂 | 体积(μl) |
qanti Tect SYBR green master mix(2×) | 10.0 |
universal Primer(10μM) | 0.8 |
miRNA Primer(10μM) | 0.8 |
cDNA模板 | 2 |
dH2O | 6.4 |
Total | 20 |
GeneSymbol | TargetScan | miRanda | CLIP-Seq | miRDB |
SKP2 | 0 | 1 | 0 | 0 |
SLAIN1 | 1 | 1 | 0 | 0 |
SLAMF7 | 0 | 1 | 0 | 0 |
SLC1A2 | 0 | 1 | 0 | 1 |
SLITRK3 | 1 | 1 | 0 | 0 |
SLITRK4 | 1 | 1 | 0 | 0 |
SLK | 0 | 1 | 0 | 0 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511029276.3A CN105617382A (zh) | 2015-12-30 | 2015-12-30 | miRNA-543-3p在帕金森病的诊断和治疗中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511029276.3A CN105617382A (zh) | 2015-12-30 | 2015-12-30 | miRNA-543-3p在帕金森病的诊断和治疗中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105617382A true CN105617382A (zh) | 2016-06-01 |
Family
ID=56032978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201511029276.3A Pending CN105617382A (zh) | 2015-12-30 | 2015-12-30 | miRNA-543-3p在帕金森病的诊断和治疗中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105617382A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106913876A (zh) * | 2017-02-24 | 2017-07-04 | 南方医科大学 | miRNA‑30a‑5p在帕金森病检测、治疗、预后靶点的应用 |
WO2019016252A1 (en) * | 2017-07-20 | 2019-01-24 | Hummingbird Diagnostics Gmbh | MIARN USED AS BIOMARKERS OF PARKINSON'S DISEASE |
CN113383090A (zh) * | 2018-12-04 | 2021-09-10 | 拉筹伯大学 | 诊断疾病状态的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103028119A (zh) * | 2011-11-22 | 2013-04-10 | 上海交通大学医学院附属瑞金医院 | 一种miR-132在制备治疗帕金森病药物中的应用 |
WO2014018650A1 (en) * | 2012-07-25 | 2014-01-30 | Rush University Medical Center | Mirnas as novel therapeutic targets and diagnostic biomarkers for parkinson's disease |
WO2015073972A1 (en) * | 2013-11-18 | 2015-05-21 | Diamir, Llc | METHODS OF USING mIRNAs FROM BODILY FLUIDS FOR DETECTION AND MONITORING OF PARKINSON'S DISEASE (PD) |
CN104903468A (zh) * | 2012-11-16 | 2015-09-09 | 西门子公司 | 用于帕金森氏病的新诊断MiRNA标志物 |
CN105063194A (zh) * | 2015-07-31 | 2015-11-18 | 北京泱深生物信息技术有限公司 | 一种帕金森的诊断标志物及其应用 |
-
2015
- 2015-12-30 CN CN201511029276.3A patent/CN105617382A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103028119A (zh) * | 2011-11-22 | 2013-04-10 | 上海交通大学医学院附属瑞金医院 | 一种miR-132在制备治疗帕金森病药物中的应用 |
WO2014018650A1 (en) * | 2012-07-25 | 2014-01-30 | Rush University Medical Center | Mirnas as novel therapeutic targets and diagnostic biomarkers for parkinson's disease |
CN104903468A (zh) * | 2012-11-16 | 2015-09-09 | 西门子公司 | 用于帕金森氏病的新诊断MiRNA标志物 |
WO2015073972A1 (en) * | 2013-11-18 | 2015-05-21 | Diamir, Llc | METHODS OF USING mIRNAs FROM BODILY FLUIDS FOR DETECTION AND MONITORING OF PARKINSON'S DISEASE (PD) |
CN105063194A (zh) * | 2015-07-31 | 2015-11-18 | 北京泱深生物信息技术有限公司 | 一种帕金森的诊断标志物及其应用 |
Non-Patent Citations (1)
Title |
---|
YI-BING OUYANG ET AL.: "Role of Astrocytes in Delayed Neuronal Death:GLT-1 and its Novel Regulation by MicroRNAs", 《ADV NEUROBIOL》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106913876A (zh) * | 2017-02-24 | 2017-07-04 | 南方医科大学 | miRNA‑30a‑5p在帕金森病检测、治疗、预后靶点的应用 |
CN106913876B (zh) * | 2017-02-24 | 2020-01-21 | 南方医科大学 | miRNA-30a-5p在帕金森病检测、治疗、预后靶点的应用 |
WO2019016252A1 (en) * | 2017-07-20 | 2019-01-24 | Hummingbird Diagnostics Gmbh | MIARN USED AS BIOMARKERS OF PARKINSON'S DISEASE |
EP4269621A3 (en) * | 2017-07-20 | 2024-04-10 | Hummingbird Diagnostics GmbH | Mirnas as biomarkers for parkinson's disease |
CN113383090A (zh) * | 2018-12-04 | 2021-09-10 | 拉筹伯大学 | 诊断疾病状态的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ataman et al. | Evolution of Osteocrin as an activity-regulated factor in the primate brain | |
Mai et al. | Intranasal administration of miR-146a agomir rescued the pathological process and cognitive impairment in an AD mouse model | |
Singh et al. | MicroRNAs in Parkinson’s disease | |
Song et al. | CSF miR-16 is decreased in major depression patients and its neutralization in rats induces depression-like behaviors via a serotonin transmitter system | |
Mushtaq et al. | miRNAs as circulating biomarkers for Alzheimer’s disease and Parkinson’s disease | |
Jayaram et al. | MicroRNA expression in the glaucomatous retina | |
Antontseva et al. | The effects of chronic stress on brain myelination in humans and in various rodent models | |
KR102626614B1 (ko) | Ad로 인한 mci 진단 마커 및 그 응용 | |
CN105617382A (zh) | miRNA-543-3p在帕金森病的诊断和治疗中的应用 | |
Gan et al. | Circular RNAs in depression: biogenesis, function, expression, and therapeutic potential | |
CN106480037A (zh) | 一种长非编码rna及在制备诊断子痫前期及靶点药物治疗中的应用 | |
Bai et al. | Identification of circular RNAs regulating islet β-cell autophagy in type 2 diabetes mellitus | |
CN106913876B (zh) | miRNA-30a-5p在帕金森病检测、治疗、预后靶点的应用 | |
Kyzar et al. | Current and future perspectives of noncoding RNAs in brain function and neuropsychiatric disease | |
Chen et al. | Comprehensive transcriptional profiling of porcine brain aging | |
Chu-Tan et al. | Functional microRNA targetome undergoes degeneration-induced shift in the retina | |
Wang et al. | CircSYNDIG1 ameliorates stress-induced abnormal behaviors by suppressing miR-344-5p in mice | |
Zhang et al. | Analysis of differential gene expression profiles uncovers mechanisms of Xuesaitong injection against cerebral ischemia-reperfusion injury | |
Majer et al. | Microdissection and transcriptional profiling: a window into the pathobiology of preclinical prion disease | |
Ke et al. | miR-34b-3p Inhibition of eIF4E Causes Post-stroke Depression in Adult Mice | |
Li et al. | Pathogenic Effects and Potential Regulatory Mechanisms of Tea Polyphenols on Obesity | |
Aydemir et al. | BDNF Measurement in Stress-Related Mood Disorders: A Review of Clinical Studies. | |
YN et al. | Treating atrial fibrillation with radiofrequency ablation to reverse changes in microRNAs regulating the ion-channel proteins. | |
CN105535977A (zh) | Nedd4-2在帕金森病治疗中的应用 | |
Ferro et al. | The cytokine receptor Fn14 regulates neuronal transcription during development and brain function in the adult |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Ji Shaogang Inventor after: Wu Xiaojuan Inventor after: Zhang Xiuping Inventor after: He Xiaoliang Inventor after: Tong Huichun Inventor after: Zhang Yunlong Inventor after: Meng Xingjun Inventor after: Zhang Wenlong Inventor before: Ji Shaogang Inventor before: Zhang Yunlong Inventor before: He Xiaoliang Inventor before: Zhang Xiuping Inventor before: Wu Xiaojuan Inventor before: Tong Huichun Inventor before: Lu Lingli Inventor before: Qin Sheng |
|
CB03 | Change of inventor or designer information | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160601 |
|
RJ01 | Rejection of invention patent application after publication |